Copper-EGCG nanoreactor orchestrates dual-metabolic assault and self-amplified cuproptosis for immunogenic prostate cancer therapy Authors: Wenya Li, Xiyao Zhang, Ying Huang, Yangyang Guo, Hao Zhang, Weiying Ge, Yuxin Xie, Yiming Li, Zhen Zhou, Wenjie Ni, Zhe Zheng, Jianmin Li, Yang Zhao Published: 2026 ABSTRACT BackgroundProstate cancer (PCa) is characterized by a unique metabolic dependency on the hyperactivated tricarboxylic acid (TCA) cycle, creating a distinct vulnerability to cuproptosis—a copper-dependent form of regulated cell death. However, metabolic plasticity allows tumor cells to evade single-pathway inhibition through compensatory glycolysis, limiting the efficacy of copper-based therapies. Therefore, there is an urgent need to develop integrated nanoplatforms capable of orchestrating a dual-pathway metabolic blockade to overcome this therapeutic resistance.ResultsHerein, we engineered a self-assembling copper-epigallocatechin gallate (EGCG) nanoreactor (Cu-EQ NP) designed to execute a synchronized dual-metabolic assault. The Cu-EQ NPs leverage the tumor microenvironment to release copper ions that trigger TCA-dependent cuproptosis, while the EGCG component simultaneously inhibits key glycolytic enzymes to prevent metabolic escape. Mechanistically, this lethality is self-amplified by EGCG-quinone-mediated depletion of glutathione (GSH) and the downregulation of the ATPase copper-transporting beta (ATP7B) efflux pump, leading to irreversible intracellular copper accumulation. Furthermore, we demonstrate that this metabolic collapse is highly immunogenic. In a syngeneic RM-1 mouse model, Cu-EQ NP-induced immunogenic cell death (ICD) released damage-associated molecular patterns (DAMPs) that successfully transformed the immunologically “cold” tumor microenvironment. This remodeling was characterized by enhanced dendritic cell maturation, M2-to-M1 macrophage repolarization, and robust infiltration of cytotoxic CD8 + T cells, resulting in potent tumor regression.ConclusionsThe Cu-EQ nanoreactor represents a precision nanomedicine strategy that converts the specific metabolic vulnerabilities of PCa into a fatal weakness. By integrating dual-metabolic disruption with robust immune activation, this platform offers a promising therapeutic paradigm for overcoming resistance in advanced prostate cancer.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-026-04617-6. Introduction Prostate cancer (PCa) is a major cause of cancer-associated mortality in men [1, 2]. Its lethal progression is inextricably linked to substantial metabolic reprogramming [3–5]. In contrast to typical prostate epithelial cells that store zinc to block aconitase and shorten the tricarboxylic acid (TCA) cycle for citrate secretion [6–8], malignant PCa cells downregulate zinc, reactivate aconitase, and restore a complete high-flux TCA cycle to support rapid proliferation [9, 10]. This acquired dependence on efficient mitochondrial metabolism indicates a therapeutically exploitable vulnerability that makes them acutely susceptible to cuproptosis [11], which is a recently elucidated type of regulated cell death driven by the loss of mitochondrial integrity and induction of proteotoxic stress via the direct interaction of copper ions with the lipoylated constituents of the TCA cycle [12, 13]. Notably, cuproptosis is often immunogenic [14, 15] and capable of triggering an immune reaction against the tumor by releasing damage-associated molecular patterns (DAMPs) that cause immunogenic cell death (ICD) [16]. Furthermore, the therapeutic potential of using cuproptosis in PCa is highlighted by the intrinsic dysregulation of copper metabolism during disease progression [17, 18]. Accumulating evidence shows that patients often exhibit elevated serum copper levels, enhanced cellular copper uptake, and androgen signaling-mediated intracellular copper accumulation [19]. Thus, cuproptosis induction emerges as a highly promising strategy against resistant PCa owing to the confluence of metabolic shift and altered copper homeostasis occurring in PCa. Despite these inherent susceptibilities, patients with advanced PCa develop strong metabolic and immunological defenses [20]. First, tumor cells exhibit metabolic plasticity, which enables them to upregulate the glycolytic flux upon disturbance of mitochondrial metabolism. This forms a “dual-engine” system that sustains the bioenergetic needs and confers resistance to single-pathway intervention [21, 22]. Second, the resulting metabolic landscape sustains an immunosuppressive tumor microenvironment (TME) [23]. Excessive lactate produced from high glycolytic flux acidifies the TME and directly impairs the function of cytotoxic effector immune cells, which potentially neutralizes the immunogenic benefits of cuproptosis [24]. Furthermore, the efficacy of cuproptosis is intrinsically constrained at the molecular level by cellular copper detoxification systems—primarily, glutathione (GSH)-mediated copper chelation and ATPase copper transporting beta (ATP7B)-dependent copper efflux [25, 26]. However, conventional copper ionophores lack the capacity to simultaneously dismantle these detoxification mechanisms, leading to suboptimal intracellular copper accumulation and therapeutic escape. These factors highlight the urgent need for a multimodal strategy that simultaneously targets metabolic flexibility, disrupts copper detoxification pathways, and remodels the immunosuppressive TME. A multitargeting agent is essential for overcoming these interconnected barriers. For example, green tea polyphenol epigallocatechin gallate (EGCG), which possesses multifaceted anti-tumor activities in addition to its conventional antioxidant and anti-inflammatory properties, could be an effective option [27]. Notably, EGCG disrupts the “dual-engine” metabolic flexibility of the tumor by inhibiting key glycolytic enzymes like hexokinase, which reduces pyruvate accumulation and simultaneously promotes acetyl-CoA conversion to rebalance the TCA cycle flux [28, 29]. This metabolic remodeling suppresses lactate-driven immunosuppression, whereas the hydroxyl-rich structure of EGCG enables metal chelation and nanoparticle formation in ion interference therapy [30]. Additionally, oxidation causes the EGCG-quinones to react readily with the amino and thiol groups of GSH, which is a novel and unique mechanism for achieving GSH depletion and oxidative stress amplification in tumor cells [31]. Despite these theoretical advantages, the direct clinical application of free EGCG and copper salts is severely hampered by the poor stability of EGCG, its rapid degradation in physiological fluids, and a lack of tumor specificity. Furthermore, simple co-administration often leads to uncontrolled precipitation and systemic toxicity rather than targeted delivery. Therefore, nanotechnology offers a vital solution to engineer a unified nanoreactor that stabilizes EGCG, coordinates copper ions, and ensures passive tumor targeting via the enhanced permeability and retention (EPR) effect. In this study, we have engineered a copper delivery nanoreactor (Cu-EQ) via the self-assembly of EGCG and copper ions to launch a coordinated disruption of the metabolic and immune defenses of aggressive PCa cells. Its core underlying mechanism involves the delivery of copper ions to induce a dual-metabolic attack through initiating cuproptosis by targeting lipoylated proteins in the hyperactive TCA cycle, while simultaneously suppressing the compensatory glycolytic pathway via EGCG-mediated inhibition of key enzymes. This synergy exerts the dual effect of crippling the energy sources and driving the cells into a fatal energy crisis. Furthermore, the nanoreactor has been engineered to withstand copper detoxification through the oxidation of EGCG to EGCG-quinone during synthesis to deplete GSH via Michael addition and prevent copper chelation. This metabolic disruption-induced ATP depletion additionally inhibits ATP7B-mediated copper efflux, which creates a self-reinforcing cycle of copper accumulation. Finally, Cu-EQ remodels the immunosuppressive TME by triggering ICD through cuproptosis and alleviating acidity-driven T-cell suppression via EGCG-mediated lactate reduction. Thus, by integrating dual metabolic targeting, copper defense disruption, and immune reprogramming, Cu-EQ presents a comprehensive paradigm for treating metabolically vulnerable and immunologically advanced PCa (Scheme 1). Scheme 1The Cu-EQ nanoreactor executes a coordinated dual metabolic–immune assault against prostate cancer. Cu-EQ NPs are self-assembled from Cu²⁺ and EGCG, accumulating in tumors via the enhanced permeability and retention (EPR) effect before dissociating in the acidic microenvironment. The released copper ions induce TCA-dependent cuproptosis, while EGCG simultaneously inhibits compensatory glycolysis, dismantling the tumor’s “dual-engine” metabolic flexibility. This lethal effect is amplified by a self-reinforcing cycle: EGCG-quinone-mediated GSH depletion and metabolic ATP loss inhibit the ATP7B efflux pump, leading to irreversible copper accumulation. Ultimately, the therapy triggers immunogenic cell death (ICD). Aided by a lactate-reduced microenvironment, this cascade promotes dendritic cell (DC) maturation, repolarizes macrophages from M2 to M1 phenotype, and activates a robust CD8⁺ T-cell immune response The Cu-EQ nanoreactor executes a coordinated dual metabolic–immune assault against prostate cancer. Cu-EQ NPs are self-assembled from Cu²⁺ and EGCG, accumulating in tumors via the enhanced permeability and retention (EPR) effect before dissociating in the acidic microenvironment. The released copper ions induce TCA-dependent cuproptosis, while EGCG simultaneously inhibits compensatory glycolysis, dismantling the tumor’s “dual-engine” metabolic flexibility. This lethal effect is amplified by a self-reinforcing cycle: EGCG-quinone-mediated GSH depletion and metabolic ATP loss inhibit the ATP7B efflux pump, leading to irreversible copper accumulation. Ultimately, the therapy triggers immunogenic cell death (ICD). Aided by a lactate-reduced microenvironment, this cascade promotes dendritic cell (DC) maturation, repolarizes macrophages from M2 to M1 phenotype, and activates a robust CD8⁺ T-cell immune response Materials and methods Materials The following reagents and chemicals were purchased: (-)-epigallocatechin-3-o-gallate (EGCG, > 98%), sodium hydroxide (NaOH), polyvinylpyrrolidone K10 (PVP K10), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), glutathione (GSH), 3,3’,5,5’-tetramethylbenzidine (TMB), ethanol, and methylene blue (MB) from Aladdin Reagent (Shanghai) Co., Ltd.; copper (II) sulfate (CuSO4) from Macklin Biochemical Co., Ltd. (Shanghai, China); dimethyl sulfoxide (DMSO) from Sigma Aldrich; TRIzol reagent from Thermo Fisher Scientific; RPMI-1640, DMEM, and fetal bovine serum (FBS) from Gibco and ProCell Life Science and Technology Co., Ltd.; and 2,7-dichlorofluorescein diacetate (DCFH-DA), Hoechst33342, 4’,6-diamidino-2-phenylindole (DAPI), Annexin V-FITC/PI apoptosis detection kit, calcein-AM and propidium iodide (PI), and JC-1 staining kit from Beyotime Inst. Biotech. (Haimen, China). The following primary antibodies were used: DLAT polyclonal antibody, LIAS polyclonal antibody, FDX1 polyclonal antibody, β-actin mouse mAb (Proteintech), α-Tublin antibody, γ-H2AX antibody, Lipoic Acid antibody, ACO2 antibody, NDUFS1 antibody and ATP7B rabbit mAb (Abcam). The following fluorescent-conjugated antibodies were obtained from BioLegend: PE/cyanine7 anti-mouse CD11b, FITC anti-mouse F4/80, APC anti-mouse CD86, PE anti-mouse CD206, PerCP anti-mouse CD11c, PE anti-mouse CD80, PE-Cy7 anti-mouse CD86, FITC anti-mouse CD3, and PerCP anti-mouse CD8a. ELISA kits for mouse interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12p70 (IL-12p70), tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ) were purchased from JINGMEI. Characterization A Zetasizer Ultra device (Malvern Instruments) was used to measure zeta potential and dynamic light scattering (DLS). UV-vis absorption spectroscopy was performed using a Spectrophotometer U-3900 (Hitachi, Japan). The TEM images were acquired using a JEOL JEM-2100 F microscope (Tokyo, Japan). A Bruker D8 ADVANCE instrument was used to record X-ray diffraction (XRD) patterns. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 600 M spectrometer. A YS EXT 8600MD instrument was used to determine the metal ion concentrations using ICP-MS. X-ray photoelectron spectroscopy (XPS) was performed using a Thermo ESCALAB 250Xi instrument. Fourier-transform infrared (FT-IR) spectra were obtained using Bruker Co. ALPHA II FT-IR Spectrometer. Fluorescence microscopy images were captured using an OLYMPUS microscope. All flow cytometry data were acquired using a Beckman Coulter CYTOFLEX S flow cytometer. The cytotoxicity assay was performed using a BioTek Epoch Microplate Spectrophotometer. qPCR was performed using a Real-Time PCR System (CFX Opus 96, BIO RAD, America). Analysis of public data sets Transcriptomic data were obtained from two primary sources: (1) 483 prostate adenocarcinoma (PRAD) samples and 51 normal prostate tissues from The Cancer Genome Atlas (TCGA), and (2) 100 normal prostate tissues from Genotype-Tissue Expression (GTEx). Raw TCGA data (STAR-aligned counts) were processed using a standardized pipeline, which included gene-level quantification using ENSEMBL gene IDs, followed by conversion to transcripts per million (TPM) values. The expected GTEx counts were normalized to TPM. Both datasets were log2-transformed (TPM + 0.001) for cross-platform comparisons. Synthesis of Cu-EQ nanoparticles 250 mg of PVP was dissolved in 50 mL deionized water. To this solution, 144 mg of anhydrous CuSO4 was added and dispersed via ultrasonication. 46 mg of EGCG was added under continuous stirring and adjusted to pH 12. The mixture was left to react overnight, and the final product was isolated via centrifugation. The collected particles were washed thrice with deionized water before freeze-drying for long-term storage. Characterization of composition and Cu2+ release The mass content of Cu2+ was determined via inductively coupled plasma mass spectrometry (ICP-MS) using a YS EXT 8600MD instrument, while the EGCG-Q loading was quantified using the Folin−Ciocalteu method according to the manufacturer’s instructions by measuring the absorbance at 760 nm against a standard EGCG-Q calibration curve. For release assays, 4 mL of the synthesized Cu-EQ NPs were placed in a dialysis bag and incubated in 400 mL of dialysis buffer (pH 5.4, 6.8, or 7.4) under continuous stirring. At the designated time points, 10 mL of the dialysis solution was sampled and replenished with an equivalent volume of fresh buffer. The collected samples were analyzed to quantify the Cu2+ concentration via ICP-MS. Michael addition reaction between EGCG-Q and GSH A 5-mL solution of EGCG (10 mg mL− 1) was heated in an oven for 24 h to oxidize EGCG to EGCG quinone (EGCG-Q). Next, 50 mg of GSH powder was introduced into the EGCG-Q solution, and the resulting mixture was sonicated to ensure the complete dissolution of GSH. This reaction mixture was transferred to an oven and heated for 24 h to generate the final EGCG-Q + GSH reaction product. The EGCG-Q, GSH, and EGCG-Q + GSH reaction products were vacuum-dried to yield powders. The powders and the physical mixture of GSH and EGCG-Q (prepared by grinding) were subjected to FT-IR spectroscopy. Furthermore, EGCG, GSH, EGCG-Q, and EGCG-Q + GSH reaction products were subjected to comparative analysis using 13C-NMR spectroscopy. D2O was used as the solvent for the process. Assessment of GSH-consumption ability DTNB reacted with GSH to produce yellow TNB2− with a distinct absorption peak at 412 nm, which was used to detect GSH consumption induced by EGCG-Q and Cu-EQ NPs. Solutions with varying concentrations of EGCG-Q and Cu-EQ NPs were mixed with GSH (50 µg mL− 1) for 30 min. The supernatant was taken out after spinning and mixed with DTNB solution (50 µg mL− 1) for 30 min, and measured the final absorption at 412 nm. POD-like activity of Cu-EQ NPs The POD-like activity of the Cu-EQ NPs was evaluated using TMB as the substrate in a PBS solution (pH = 5.5) with hydrogen peroxide (H2O2). Cu-EQ NPs (5 µL) were added to PBS (pH = 5.5) containing 100 µL of H2O2 (1 M) and 8 µL of TMB (5 mg mL− 1). Reaction progress was monitored by recording the absorbance at 652 nm at specified time intervals (0, 2, 3, 5, and 7 min) using a UV-Vis spectrophotometer. Additionally, Cu-EQ NPs at different concentrations were added to PBS containing 100 µL of H2O2 (1 M) and 8 µL of TMB (5 mg mL− 1). After 5 min of reaction, absorbance was measured at 652 nm. Investigation of ·OH generation Cu-EQ NPs at various concentrations were mixed with H2O2 (100 mM) and MB (4 µg mL− 1), and absorbance was recorded at 660 nm after 5 min. Next, Cu-EQ NPs (40 µg mL− 1) and varying concentrations of H2O2 (5, 10, 20, 40, 60, and 80 mM) were added to PBS (pH = 5.5) containing MB. Absorbance was measured at 660 nm after 5 min. Electron spin resonance (ESR) spectroscopy analysis was conducted using DMPO and TEMP as spin traps to identify the ROS species (·OH, O2•⁻, and 1O2) generated by Cu-EQ NPs upon H2O2 treatment. Cell culture The study utilized several cell lines, including BPH-1, SV-HUC-1 (SV40-immortalized human urothelial), RM-1, PC3, DU45, RAW 264.7, and bone marrow-derived dendritic cells (BMDCs). BPH-1, SV-HUC-1, PC3, DU145, RM-1, and RAW 264.7 were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China), and were confirmed via STR cell sequencing and certified as being free of mycoplasma contamination. These were kept at 37 ℃ in an incubator with 5% CO2 and humidity. RM-1, PC3, DU145, BPH-1, and BMDCs were grown in RPMI-1640, while RAW 264.7 macrophages required DMEM medium. All media contained 10% FBS and 1% penicillin–streptomycin. A dedicated complete medium provided by the manufacturer was used to grow SV-HUC-1 cells. Cellular uptake analysis PC3 or DU145 cells were incubated with Rhodamine B-labeled Cu-EQ NPs (10 µg mL− 1) for varying incubation periods. Following incubation, the cells were marked with Hoechst 33,342 (10 µM) for 5 min and observed by an inverted fluorescence microscope. Cell viability assay BPH-1, SV-HUC-1, PC3, DU145, and RM-1 cells were incubated for 24 h in medium containing the indicated materials (PBS, EGCG, EGCG-Q, Cu2+, or Cu-EQ NPs) at the desired concentrations. Following treatment, a CCK-8 solution was introduced into each well for 2 h at 37 °C, following by measuring absorbance at 450 nm using enzyme microplate reader. Cell viability was determined as: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{Cell}{\:viability}{\:(\%)=}\frac{{(}{{OD}}_{{450,\:}{sample}}{-}{{OD}}_{{450,\:}{blank}}{)}}{{(}{{OD}}_{{450,\:}{control}}{-}{{OD}}_{{450,\:}{blank}}{)}}{\times100\%}$$\end{document} In vitro cellular ROS generation PC3 or DU145 cells were subjected to different treatments (PBS, EGCG, EGCG-Q, Cu2+, and Cu-EQ NPs) for 24 h. After treatment, the cells were treated with DCFH-DA (10 µM) for 40 min and Hoechst 33342 for 5 min. The fluorescent images were captured. Alternatively, the stained cells were harvested for quantitative analysis of ROS generation using flow cytometry. Detection of intracellular •OH PC3 cells were administered with different treatments for 24 h. After that, the cells were incubated with C11 dye diluted 1:1000 for 30 min and stained with Hoechst 33342 for 5 min. Fluorescent images were acquired using an inverted fluorescence microscope. Mitochondrial membrane potential (MMP) detection PC3 cells were subjected to different treatments for 24 h. Following treatment, the cells were incubated with the JC-1 staining probe according to the manufacturer’s protocol. An inverted fluorescence microscope was used to acquire images, and JC-1 monomers (indicating depolarized mitochondria) were detected in the green channel (Ex: 488 nm, Em: 510–540 nm), whereas JC-1 aggregates (indicating polarized mitochondria) were detected in the red channel (Ex: 543 nm, Em: 570–620 nm). Colony formation assay PC3 or DU145 cells were exposed to the different treatments for 24 h, the cells were further cultured for 1–2 weeks until visible colonies formed, which were fixed with 4% paraformaldehyde (PFA) for 15 min. The plates were rinsed extensively with PBS and stained for 1 h with a 0.1% crystal violet solution at 4 °C. The proliferation and growth potentials of the cells were evaluated by counting the number of colonies. Cell apoptosis assay After 24-hour treatment with the materials, PC3 or DU145 cells were collected using EDTA-free trypsin, resuspended in 100 µL of binding solution containing Annexin V-FITC (5 µL) and PI (10 µL), and incubated for 10 min at room temperature in the dark. The samples were flow-cytometrically examined. Calcein-AM/Propidium Iodide (PI) Co-staining assay Following 24 h of treatment, PC3 or DU145 cells were co-stained with Calcein-AM (10 µg mL− 1) and PI (5 µg mL− 1) for 30 min. Stained cells were seen using an inverted fluorescence microscope. Western blot analysis PC3 cells were treated with different materials for 24 h, and cellular proteins were extracted on ice for 40 min using 100 µL RIPA lysis buffer with protease inhibitors. The lysates were collected and quantified using a BCA protein assay kit. Equal quantities of protein were heat-denatured at 95 °C for 10 min in loading buffer and separated using 10% SDS-PAGE. Proteins were transferred to PVDF membranes, blocked with 5% non-fat milk, and incubated at 4 °C with primary antibodies against LIAS, FDX1, Lipoic Acid, ACO2, NDUFS1, γ-H2AX, ATP7B, α-Tubulin, or β-Actin. After four washes, membranes were incubated for 1 h with HRP-conjugated secondary antibodies. An enhanced chemiluminescence (ECL) imaging technique showed protein bands after four washes. Intracellular GSH assay Relative intracellular glutathione (GSH) levels were quantified using a commercial GSH assay kit (Solarbio). Briefly, PC3 cells with different treatments were collected, and cell number was counted. The intracellular GSH content was determined according to the manufacturer’s instructions. Comet assay The single-cell gel electrophoresis (comet) assay was performed to detect DNA damage. PC3 cells were seeded and cultured until they reached the logarithmic growth phase. After 24 h of treatment, the cells were collected via trypsin digestion, and the medium was discarded. The cells were resuspended in serum-free medium, and their concentration was adjusted to 1 × 105 cells/mL. A mixture of the cell suspension and agarose was spread rapidly onto pre-coated slides to form an even cell layer, which was solidified at 4 °C. Then, the slides were treated with lysis buffer to remove cell membranes and proteins and release the DNA into the agarose. Then, the slides were immersed in electrophoresis buffer and subjected to electrophoresis at 0.5–1 V/cm for 20–30 min. After electrophoresis, the slides were neutralized and stained with PI. An inverted fluorescence microscope was used to capture the images, and DNA damage was quantified using ImageJ software based on parameters such as comet tail length and tail-to-head ratio. Seahorse XF metabolic analysis The real-time oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were monitored using a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies). PC3 cells were seeded in XF96 cell culture microplates at a density of 5,000 cells/well and treated with indicated formulations for 24 h. For OCR, the culture medium was replaced with Seahorse XF base medium supplemented with 1.0 mM pyruvate, 2.0 mM glutamine, and 10 mM glucose. The OCR was recorded following the sequential injection of oligomycin (1.5 µM), FCCP (1.5 µM), and rotenone/antimycin A (1.0 µM). For ECAR, cells were incubated in glucose-free XF base medium supplemented with 2.0 mM glutamine. The ECAR was measured following the sequential injection of glucose (10 mM), oligomycin (1.5 µM), and 2-deoxyglucose (2-DG, 50 mM). Enzyme activity assay To measure glycolytic enzyme activity, the treated RM-1 cells were harvested via centrifugation after incubation and washed with cold PBS. Extraction buffer (1 mL) was added, and the cells were lysed on ice via ultrasonication. The resulting lysates were clarified by performing centrifugation (8,000 × g for 10 min at 4 °C), and the supernatant was collected for analysis. The activities of hexokinase (HK), phosphofructokinase (PFK), pyruvate kinase (PK), and lactate dehydrogenase (LDH) in the lysates were measured using commercial assay kits (Abbkine), according to the manufacturer’s protocols. Measurement of glucose uptake and lactate release PC3, DU145, and RM-1 cells were incubated with different materials for 24 h. To determine glucose consumption, 2.5 µL of supernatant from each group was collected and mixed with 250 µL of a glucose assay working solution (Jiancheng), and absorbance was measured at 505 nm. For the lactate release assay, 20 µL of culture supernatant was analyzed according to the instructions of the lactate assay kit (Jiancheng) and measured absorbance at 530 nm. Intracellular ATP content measurement PC3 cells were seeded onto 6-well plates and treated for 24 h. The intracellular ATP levels were quantified using a commercial ATP assay kit (Abbkine). qPCR analysis of glycolysis-related gene expression Total RNA was isolated from RM-1 cells treated with 1 mL of TRIzol reagent/well. An equivalent quantity of RNA from each sample was reverse-transcribed into cDNA using the ReverTra Ace qPCR RT Master Mix on a thermal cycler. The resulting cDNA was used as the template for qPCR, which was performed on a CFX Opus 96 Real-Time PCR System (Bio-Rad, Hercules, CA, USA) using the SYBR Green master mix. Relative gene expression levels were normalized to that of β-actin as the endogenous control and calculated using the 2⋀(−∆∆Ct) method. Finally, changes in the expression of the target genes under different treatment conditions were analyzed. Lactate dehydrogenase (LDH) assay The release of LDH from treated RM-1 cells, which is an indicator of cytotoxicity, was quantified using a commercial LDH Activity Assay Kit (Abbkine) according to the manufacturer’s instructions. Quantification of HMGB1, IL-1β, and ATP secretion The concentrations of HMGB1, IL-1β, and ATP released into the cell culture supernatants after 24 h of treatment were determined using commercial ELISA kits (Jingmei) for HMGB1 and IL-1β, and an ATP assay kit for ATP by following the manufacturer’s protocols. CRT exposure and HMGB1 translocation After RM-1 cells were treated with different materials for 24 h, they were fixed with 4% PFA for 10 min and permeabilized with 0.3% Triton X-100 for 10 min (for HMGB1 only). The cells were incubated overnight at 4 °C with primary antibodies against CRT (1:200) and HMGB1 (1:200) after blocking with 5% BSA for 1 h. The cells were incubated in the dark with Alexa Fluor 488- or Alexa Fluor 555-conjugated secondary antibodies (1:200) for 1 h. Finally, after three additional PBS washes, the nuclei were counterstained with DAPI for 5 min and observed by fluorescence microscopy. In vitro macrophage polarization To generate an M2-polarized phenotype, RAW 264.7 macrophages were cultured with IL-4 (25 ng mL− 1) for 12 h. The M2-polarized macrophages were exposed for 6 h to conditioned supernatants collected from RM-1 cells that had been previously subjected to various treatments. After incubation, the macrophages were harvested and stained for flow cytometric analysis using the following antibodies: FITC-anti-F4/80, APC-anti-CD86, and PE-anti-CD206. Macrophage polarization status was quantified using flow cytometry. The supernatant from the final culture was collected to measure IL-12 and IL-10 levels using ELISA kits (Jingmei). Analysis of in vitro DCs maturation Bone marrow was harvested by flushing the femurs and tibias of 8-week-old male C57BL/6 mice with PBS. The isolated cells were seeded and cultured in RPMI 1640 medium with GM-CSF (20 ng mL− 1) and IL-4 (20 ng mL− 1), and the medium was replenished every 2 days. On day 7, the population of nonadherent and loosely adherent immature dendritic cells (DCs) was collected for use in the maturation assay. For the maturation assay, immature DCs were incubated for 24 h with conditioned supernatants from RM-1 cancer cells that were subjected to previous treatments. Following incubation, the DCs were harvested, washed thrice with PBS, and stained for 30 min with the following antibodies: PerCP anti-mouse CD11c, PE anti-mouse CD80, and PE-Cy7 anti-mouse CD86. The maturation status of DCs was subsequently quantified using flow cytometry. Hemolysis assay Erythrocytes (RBCs) were collected from the whole blood of C57BL/6 mice. After washing the RBC pellet thrice with PBS, the cells were resuspended in different solutions: PBS, deionized water, and PBS containing various concentrations of Cu-EQ NPs (12.5–400 µg mL− 1). Then, the samples were centrifuged to pellet the intact RBCs. The absorbance of the supernatant from each sample was measured at 540 nm, and the hemolysis percentage was calculated.\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{Hemolysis}{\:(\%)=}\frac{{(}{{OD}}_{{540,\:}{sample}}{-}{{OD}}_{{540,\:}{negative}{}{control}}{)}}{{(}{{OD}}_{{540,\:}{positive}{}{control}}{-}{{OD}}_{{540,\:}{negative}{}{control}}{)}}{\times100\%}$$\end{document} Tissue Distribution in Vivo To determine the in vivo biodistribution of the NPs, mice bearing PC3 tumors received a single intravenous injection of Cu-EQ NPs. At designated time points (0, 12, and 24 h and days 3 and 7) following administration, the mice were euthanized by CO2 asphyxiation at the end of the study, using a slow fill rate of 30% of the chamber volume per minute. The major organs (heart, liver, spleen, lungs, kidneys, and brain) and tumors were excised and weighed. The tissues were digested in a nitric acid/hydrogen peroxide (HNO3/H2O2) mixture for 7 days. The copper ion content in each digested tissue sample was quantified using ICP-MS. In vivo biodistribution and imaging To track the systemic distribution, Cu-EQ NPs were fluorescently labeled with indocyanine green (ICG). RM-1 tumor-bearing C57BL/6 mice were intravenously injected with ICG-labeled Cu-EQ NPs. At predetermined time points (0, 2, 6, 12, 18, 24, 36, and 48 h), in vivo fluorescence imaging was performed using a PerkinElmer IVIS Spectrum imaging system. Subsequently, major organs (heart, liver, spleen, lungs, kidneys, and brain) and tumors were harvested for ex vivo imaging and semi-quantitative analysis of mean fluorescence intensity (MFI). In vivo antitumor efficacy Male BALB/c nude mice (4-week-old) and C57BL/6 mice (4-week-old) were obtained from SPF (Beijing) Biotechnology Co. Ltd. All animal experiments were performed in accordance with the Institutional Animal Care and Use Committee of Tianjin University of Traditional Chinese Medicine (Approval number: TCM-LAEC2024094w0929) and local legislation and institutional policies for animal welfare. A prostate cancer xenograft model was established by subcutaneously inoculating BALB/c nude mice in the inguinal region with a PC3 cell suspension (3 × 106 cells/mouse). Once the tumors reached an approximate volume of 50 mm3, the mice were randomized into four treatment groups (n = 5 per group): (1) PBS, (2) EGCG-Q, (3) Cu2+, and (4) Cu-EQ NPs. Each group received treatment (15 mg kg− 1) via tail vein injections once in 2 days for 2 weeks. Anesthesia was induced and maintained using a vaporized 2% isoflurane/oxygen mixture via an inhalation system during the injection procedure. Tumor growth and body weight were monitored every 2 days throughout the treatment period. Tumor volumes were calculated using the following formula: V = (length × width2)/2. At the conclusion of the study on day 14, the mice were euthanized by CO2 asphyxiation, using a slow fill rate of 30% of the chamber volume per minute. The excised tumors were photographed and weighed to assess antitumor efficacy. The major organs and tumor tissues were collected and sectioned for histological analysis using H&E staining, Ki67 immunohistochemistry to assess cell proliferation, and TUNEL staining to detect apoptotic cells that were visualized using fluorescence microscopy for quantifying the apoptosis level. Additionally, markers of cuproptosis, including LIAS (1:200), FDX1 (1:200), and DLAT (1:1000), were detected via standard immunohistochemical (IHC) protocols involving heat-induced antigen retrieval and DAB-based visualization. In vivo antitumor immunity An immunocompetent mouse model of prostate cancer was established by subcutaneously injecting C57BL/6 mice with RM-1 cells (5 × 105 cells/mouse) into the inguinal region. Once the tumors reached a volume of approximately 50 mm3, the mice were randomized into five treatment groups (n = 5 per group) as follows: (1) PBS, (2) EGCG, (3) EGCG-Q, (4) Cu2+, and (5) Cu-EQ NPs. Treatments were administered via tail vein injection once every 2 days for 2 weeks, and tumor growth was monitored throughout the study. At the endpoint of the study, the tumors, spleens, and lymph nodes were harvested for immunological analysis. To analyze macrophage polarization, the excised tumors were processed into single-cell suspensions via homogenization and filtration. These cells were stained with PE/cyanine7-anti-CD11b, FITC-anti-F4/80, APC-anti-CD86, and PE-anti-CD206 antibodies for flow cytometric analysis of TAM phenotypes. For the DC maturation analysis, single-cell suspensions were prepared from both tumors and lymph nodes, followed by staining with antibodies against PerCP-CD11c, APC-CD86, and PE-CD80 for flow cytometry. To assess T-cell activation, the spleens were processed into single-cell suspensions. The splenocytes were stained with FITC-anti-CD3 and PerCP-anti-CD8a antibodies for flow cytometric analysis. The concentrations of various cytokines (TNF-α, IFN-γ, IL-6, IL-10, and IL-12) in the tumor tissue supernatants were quantified using commercial ELISA kits (Jingmei). Intratumoral expression of CRT, CD8, and HMGB1 was further visualized through standard immunofluorescence (IF) staining using Alexa Fluor-labeled secondary antibodies and DAPI counterstaining. Biosafety evaluation For biosafety evaluation, the mice received the corresponding treatments via intravenous injection. Ten days after the final treatment, blood samples were drawn for the analysis of key biochemical parameters. The blood samples were centrifuged (5000 rpm for 5 min) to isolate the plasma. An automated biochemical analyzer was used to measure clinical parameters including key markers of liver function (ALT, AST, ALP, and ALB) and kidney function (BUN and CREA). Statistical analysis All experiments were performed a minimum of three times, and the quantitative results are expressed as the mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to determine the statistical differences among experimental groups. All calculations were performed using the GraphPad Prism 10 software. P values were considered significant as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Results and discussion Copper metabolism vulnerabilities and energy reprogramming induce cuproptosis susceptibility in PCa cells Copper homeostasis dysregulation in PCa is well established; however, a systematic data-driven mapping of the affected molecular circuitry is lacking [17]. This analysis used the power of the combined TCGA and GTEx datasets to define the transcriptional landscape of copper metabolism in PCa, which revealed significant disruptions in key regulatory molecular pathways (Fig. 1A). Altered expression patterns were observed in the genes responsible for copper acquisition, transport, storage, and efflux. Notably, genes such as the metallothionein (MT) family that are crucial for copper storage were predominantly downregulated in prostate cancer tissues (Fig. 1B), which indicates a diminished copper-buffering capacity in PCa cells. A simultaneous expression analysis of core cuproptosis-related genes (such as FDX1, LIAS, and DLAT) showed predominant upregulation in tumor tissues (Fig. 1C), which establishes a baseline for cuproptosis susceptibility. Collectively, these findings highlight the potential vulnerability of prostate cancer cells to copper-induced stress due to the disruption of copper homeostasis. In addition to copper metabolism, PCa is well characterized by its unique and flexible metabolic adaptations. We further characterized the metabolic state of PCa in the TCGA-GTEx dataset by performing gene set variation analysis (GSVA) of the key energy metabolic pathways. The GSVA scores showed significant upregulation of the TCA cycle (Fig. 1D), glycolysis (Fig. 1E), and OXPHOS (Fig. 1F) in prostate tumor tissues compared with normal tissues. This observation confirmed that the PCa cells in this large-scale dataset maintain a “dual-engine” metabolic profile that is characterized by robust mitochondrial respiration (high TCA cycle and OXPHOS) with an enhanced glycolytic flux. This metabolic reprogramming creates a high-energy demand state, which significantly implies that PCa cells develop metabolic dependencies that may confer susceptibility to TCA cycle-dependent cuproptosis. We validated these findings experimentally by assessing the expression levels of selected cuproptosis-related genes (FDX1, LIAS, and DLAT) in PCa cells (PC3) and human prostate epithelial cells (BPH-1). We performed western blotting (Fig. 1G–J) and quantitative polymerase chain reaction (qPCR) analysis of selected genes such as ATP7B, SLC31A1, MTF1, COX17, PDHA, and GLS (Fig. 1K, S1A). The in vitro results were consistent with the bioinformatics findings and indicated the upregulation of cuproptosis effectors in PC3 cells compared with that in BPH-1 cells. Collectively, these multi-omic and experimental validations showed that targeting the copper metabolic vulnerability embedded within an active mitochondrial energy production axis simultaneously with the robust glycolysis could provide new avenues for precise targeting in PCa management. Collectively, these data show that PCa harbors a convergence of vulnerabilities with disrupted copper homeostasis, primed cuproptosis machinery, and hypermetabolic state that is highly dependent on the TCA cycle. This creates a compelling rationale for the development of therapeutic strategies that exploit these interlinked features. We hypothesized that a synthetic lethal approach that simultaneously induces cuproptosis to cripple the TCA cycle and inhibits the compensatory glycolytic pathway would lead to catastrophic metabolic collapse in cancer cells. We tested this hypothesis at the pharmacological level by combining the cuproptosis inducer Elesclomol-Cu (Eles-Cu) with the glycolysis inhibitor 2-Deoxy-D-glucose (2-DG) or the BET inhibitor JQ-1, which regulates metabolic programs. According to the heatmap analyses and combination index (CI) calculations, both drug combinations exhibited strong synergistic anti-cancer effects in PCa cell lines, with CI values consistently below 1 (Figure S1). This provides a powerful proof-of-concept that validates the dual-metabolic assault strategy and enables the development of an integrated therapeutic agent. Fig. 1Dysregulation of copper metabolism and metabolic reprogramming in prostate cancer.(A) Comparative expression of key copper homeostasis regulators, (B) metal-binding metallothionein (MT) family genes, and (C) cuproptosis-related genes. All comparisons are between normal tissue and prostate adenocarcinoma (PRAD) tumor samples using data sourced from the TCGA and GTEx databases. (D-F) Gene set variation analysis (GSVA) scores comparing the (D) tricarboxylic acid (TCA) cycle, (E) glycolysis, and (F) oxidative phosphorylation (OXPHOS) pathways within the combined TCGA-GTEx dataset. (G) Western blotting analysis with (H–J) corresponding quantitative analysis comparing prostate cancer cells (PC3) with human prostate epithelial cells (BPH-1). (K) Quantitative polymerase chain reaction (qPCR) analysis validating target gene expression in PC3 versus BPH-1 cells. Results are described as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Dysregulation of copper metabolism and metabolic reprogramming in prostate cancer.(A) Comparative expression of key copper homeostasis regulators, (B) metal-binding metallothionein (MT) family genes, and (C) cuproptosis-related genes. All comparisons are between normal tissue and prostate adenocarcinoma (PRAD) tumor samples using data sourced from the TCGA and GTEx databases. (D-F) Gene set variation analysis (GSVA) scores comparing the (D) tricarboxylic acid (TCA) cycle, (E) glycolysis, and (F) oxidative phosphorylation (OXPHOS) pathways within the combined TCGA-GTEx dataset. (G) Western blotting analysis with (H–J) corresponding quantitative analysis comparing prostate cancer cells (PC3) with human prostate epithelial cells (BPH-1). (K) Quantitative polymerase chain reaction (qPCR) analysis validating target gene expression in PC3 versus BPH-1 cells. Results are described as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Engineering stimuli-responsive Cu-EQ nanoreactor for coordinated copper delivery and GSH depletion Based on the established vulnerabilities of PCa, we engineered the Cu-EQ nanoreactor, which is a dual-functional platform designed to co-deliver copper ions and a GSH-depleting agent. This synthesis combined the intrinsic properties of EGCG and copper sulfate (CuSO4), with polyvinylpyrrolidone (PVP) acting as the stabilizer. The core of this design involves a one-pot reaction under alkaline conditions (pH = 12), which is hypothesized to drive the self-assembly of the metal–phenolic network and simultaneously oxidize EGCG into its highly reactive quinone form (EGCG-Q). This process yielded the final Cu-EQ nanoparticles (NPs) after 12 h and was visually confirmed based on immediate colloidal formation and color evolution from brown (deprotonated EGCG) to characteristic green (Figure S2). Transmission electron microscopy (TEM) analysis showed that the Cu-EQ NPs maintained a monodisperse distribution with a sunflower seed-like morphology and were approximately 60 nm in size with distinct lamellar nanostructures that were indicative of enhanced catalytic potential (Fig. 2A). Optimal synthesis was found to occur at room temperature because higher temperatures led to irregular products (Figure S3). The PVP-stabilized Cu-EQ NPs showed excellent colloidal stability in various biological media and maintained a consistent hydrodynamic diameter of approximately 90 nm and zeta potential of approximately − 20 mV for more than 7 days (Figure S4A–C). These findings confirmed their suitability for biomedical applications. Compositional and structural analyses validated the successful formation of the nanoreactors. UV-Vis spectroscopic analysis of the Cu-EQ NPs showed significant peak broadening (200–300 nm range), accompanied by a 12-nm bathochromic shift relative to that of free EGCG (Fig. 2B). The appearance of a low-intensity absorption band (550–800 nm) confirmed metal–ligand coordination through the carbonyl oxygen atoms (Figure S5A). Notably, this coordination geometry remained consistent across different precursor ratios (Figure S5B). However, the 9:1 (Cu: EGCG) ratio resulted in a high nanoparticle yield during synthesis and was selected for scaled-up production. X-ray diffraction (XRD) patterns showed that the Cu-EQ NPs exhibited predominantly amorphous structures with embedded nanocrystalline domains, as evidenced by the broad diffraction peaks superimposed with weak crystalline signatures (Fig. 2C). Moreover, TEM elemental mapping and energy dispersive spectroscopy (EDS) analysis verified the homogeneous incorporation of all constituent elements within the nanoparticle (Fig. 2D, E) with copper localization correlating precisely with organic component distributions. X-ray photoelectron spectroscopy (XPS) analysis of the Cu-EQ NPs confirmed the presence of Cu, C, N, and O (Fig. 2F). High-resolution scans showed critical chemical state information. The Cu 2p3/2 and 2p1/2 regions exhibited characteristic doublets at 934.5/954.6 eV (Cu2+) and 932.8/952.7 eV (Cu+), respectively, which confirmed the presence of mixed valence states (Fig. 2G). Deconvolution of the C 1s spectrum identified three components: 284.8 eV (C = C/C-C), 286.4 eV (C-O), and 288.5 eV (O = C–O) (Figure S6A). The O 1s region exhibited a Cu–O bond signal at 529.95 eV along with peaks at 531.5 eV (C = O) and 533.3 eV (C-O), which verified metal–phenolic coordination (Figure S6B). Based on inductively coupled plasma mass spectrometry (ICP-MS) measurements, the copper content in the Cu-EQ NPs was determined to be 37.12 wt% ± 0.91 wt%. Concurrently, the EGCG-Q loading was quantified using the Folin−Ciocalteu method, revealing a mass content of 14.49 wt% ± 1.45 wt% based on the standard calibration curve in Figure S7A. Furthermore, pH-dependent Cu2+ release profiles showed 3.8-fold greater ion liberation at pH 5.6 (45.89%) than at pH 7.4 (12.98%) in 24 h (Figure S7B), which confirmed acid-triggered dissociation. We sought to verify the two key functional pillars of our design, which were the oxidation of EGCG to its GSH-depleting quinone form and stimuli-responsive release of copper. The oxidation process during synthesis was monitored using UV-Vis spectroscopy, which showed the kinetic evolution from deprotonated EGCG to the final quinone structure (Figure S8A). Polyphenols are prone to oxidation to quinones under aerobic conditions, and the resulting quinones exhibited high reactivity towards thiol and amine groups via Michael addition [32]. We unequivocally proved the GSH-depleting capability of EGCG-Q by allowing it to react with GSH and analyzing the products. As shown in Fig. 2H, oxidized EGCG (EGCG-quinone, EGCG-Q) effectively depleted GSH in the cancer cells. Fourier-transform infrared (FT-IR) spectral analysis of EGCG-Q showed weakening of the phenolic O–H stretching bands at 3556 cm− 1, 3479 cm− 1, and 3357 cm− 1; reduction of the C–O stretching vibration band at 1291 cm− 1; and broadening of the C = O stretching vibration at 1691 cm− 1, thereby confirming the oxidation of EGCG to EGCG-Q (Fig. 2I) [33]. The reaction of EGCG-Q with GSH in aqueous solution followed by lyophilization yielded FT-IR spectra showing the complete disappearance of the characteristic GSH vibrations N–H (3252 cm− 1) and S–H (2525 cm− 1), whereas these peaks remained evident in the physical mixtures. This indicated that the thiol and amine groups of GSH reacted with EGCG-Q. 13C-NMR results further verified the oxidation through the disappearance of the phenolic carbon signals of EGCG (95.84, 95.07 ppm) and the emergence of quinoid carbon resonances (Figure S8B). Comparative analysis of the EGCG–Q/GSH reaction mixture showed two diagnostic adduct signatures: 56.9 ppm (C–N group) (Fig. 2J) and 29.38 ppm (C–S group) (Fig. 2K). This indicated the formation of covalent EGCG–Q adducts through both amine (EGCG-amino) and thiol (EGCG-thiol) conjugation pathways [34]. Alkaline conditions accelerated EGCG oxidation, as was evidenced by the UV-Vis spectral evolution. The 274 nm peak immediately disappeared, and phenolic hydroxyl deprotonated to phenolate anion, which resulted in a 328-nm peak enhancement. This was followed by a progressive 328-nm decay with concurrent 374-nm growth (quinone formation) that correlated with the nanoparticle synthesis kinetics (Figure S8A). FT-IR analysis confirmed the structural transformation through the emergence of a Cu–O stretching vibration (717.15 cm− 1) and disappearance of the phenolic–OH stretch (3484 cm− 1) (Fig. 2L). This validated the EGCG-Q/Cu2+ coordination in Cu-EQ NP formation. Thus, copper ion-mediated nanocatalyst Cu-EQ NPs that depleted GSH and inhibited glycolysis were successfully synthesized. Fig. 2Synthesis and characterization of Cu-EQ nanoparticles. (A) Transmission electron microscopy (TEM) images of Cu-EQ NPs. (B) UV-Vis absorption spectra of different reactants and intermediates (EGCG, Cu-EQ, CuSO4, and PVP). (C) X-ray diffraction (XRD) pattern of Cu-EQ NPs. TEM-mapping (D) and energy dispersive spectrum (E) of Cu-EQ NPs. (F) X-ray photoelectron spectroscopy (XPS) survey spectrum of Cu-EQ NPs. (G) High-resolution XPS spectra of Cu 2p in Cu-EQ NPs. (H) Proposed reaction mechanism of EGCG oxidation to quinone, followed by GSH conjugation. (I) Fourier-transform infrared spectroscopy (FT-IR) spectra of EGCG, GSH, EGCG-Q, EGCG-Q + GSH, and physical mixture of EGCG-Q + GSH. (J, K) 13C nuclear magnetic resonance (NMR) spectra of EGCG, GSH, EGCG-Q, and EGCG-Q + GSH. (L) FT-IR spectra of Cu-EQ NPs and different reactants Synthesis and characterization of Cu-EQ nanoparticles. (A) Transmission electron microscopy (TEM) images of Cu-EQ NPs. (B) UV-Vis absorption spectra of different reactants and intermediates (EGCG, Cu-EQ, CuSO4, and PVP). (C) X-ray diffraction (XRD) pattern of Cu-EQ NPs. TEM-mapping (D) and energy dispersive spectrum (E) of Cu-EQ NPs. (F) X-ray photoelectron spectroscopy (XPS) survey spectrum of Cu-EQ NPs. (G) High-resolution XPS spectra of Cu 2p in Cu-EQ NPs. (H) Proposed reaction mechanism of EGCG oxidation to quinone, followed by GSH conjugation. (I) Fourier-transform infrared spectroscopy (FT-IR) spectra of EGCG, GSH, EGCG-Q, EGCG-Q + GSH, and physical mixture of EGCG-Q + GSH. (J, K) 13C nuclear magnetic resonance (NMR) spectra of EGCG, GSH, EGCG-Q, and EGCG-Q + GSH. (L) FT-IR spectra of Cu-EQ NPs and different reactants Cu-EQ nanoreactors execute dual-catalytic assault to disrupt redox homeostasis A primary obstacle to copper-based therapies is the robust antioxidant defense system of aggressive cancer cells—particularly the GSH system, which directly chelates copper ions and neutralizes oxidative stress. The Cu-EQ nanoreactor was engineered to systematically dismantle this defense through a multipronged catalytic assault that includes direct GSH depletion via Michael addition and Fenton-like conversion of tumor-derived H2O2 to hydroxyl radicals (•OH). First, we confirmed its ability to deplete GSH, which is a critical prerequisite for effective cuproptosis. We used Ellman’s assay with 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB). This thiol-specific probe generates yellow-colored TNB2− (λmax = 412 nm) upon GSH reaction (Fig. 3A, S9). The dose-dependent decrease in TNB2− absorbance as EGCG-Q concentration increased (Fig. 3B) confirmed competitive GSH consumption through quinone–thiol conjugation. Furthermore, Cu-EQ NPs showed enhanced glutathione peroxidase (GPx)-like activity and catalyzed GSH oxidation to glutathione disulfide (GSSG) (Figs. 3C–D), which compromised cellular antioxidant defenses. This dual-action depletion through the combination of rapid and direct conjugation by EGCG-Q with sustained catalytic oxidation via GPx-like activity is a significant advantage of this nanoreactor. This self-reinforcing process ensured effective and prolonged disruption of the cellular GSH pool, which crippled the primary defense against copper toxicity and oxidative stress. In addition to neutralizing cellular defenses, the designed Cu-EQ NPs launched a direct oxidative attack by converting endogenous H2O2 in the TME into highly toxic hydroxyl radicals (•OH). The peroxidase (POD)-like activity of the Cu-EQ NPs was quantitatively assessed using 3,3′,5,5′-tetramethylbenzidine (TMB) as the chromogenic substrate. Catalytic oxidation of colorless TMB to blue oxTMB (λmax = 370/652 nm) occurred via the generation of hydroxyl radicals (•OH) through Fenton chemistry in the H2O2/Cu-EQ NPs system (Figs. 3E, F). Both dose- and time-dependent experiments showed progressive enhancement of oxTMB formation as nanoparticle concentration (0–4 µg/mL) and reaction duration (0–7 min) increased (Figs. 3G–H). These results confirmed the robust POD-mimetic activity. Notably, catalytic efficiency persisted at ultralow concentrations (4 µg/mL), which may be attributed to efficient Cu+/Cu2+ redox cycling, phenol-to-quinone transition that facilitates Cu2+ reduction, and enhanced electron transfer at the nano-bio interface. Furthermore, we evaluated the POD-mimetic activity of the Cu-EQ NPs using methylene blue (MB) decolorization assays. The hydroxyl radicals generated by the NPs oxidized MB to hydroxylated derivatives (MB-OH), which manifested as a visual transition from blue to colorless and progressive attenuation of the 665-nm absorption band (Fig. 3I). Dose-response studies showed concentration-dependent activity, with MB decomposition rates increasing proportionally with both Cu-EQ NP (0–40 µg/mL) (Fig. 3J) and H2O2 (0–80 mM) (Fig. 3K) concentrations. Time–course analysis indicated a direct correlation between •OH production (as evidenced by the MB degradation rate) and reaction duration in the H2O2/Cu-EQ NPs system (Fig. 3L). To further verify the specific types of ROS generated by the catalytic process, electron spin resonance (ESR) spectroscopy was performed using DMPO and TEMP as spin traps (Figure S10). In the presence of H2O2, Cu-EQ NPs exhibited a characteristic 1:2:2:1 quadruple signal of DMPO-·OH and distinct signals of O2•⁻, as well as a typical 1:1:1 triplet signal of 1O2 (Figure S10A–C). This multimodal ROS generation is primarily attributed to the sophisticated redox cycling between the inherent Cu+ and Cu2+ species within the nanoreactor, where the Cu+/Cu2+ transition facilitates not only the Fenton-like production of ·OH but also the energy/electron transfer to induce 1O2 and O2•⁻. In summary, these findings show that the Cu-EQ nanoreactor functions as a sophisticated catalytic platform that executes a “dual-hit” redox modulation strategy. It synchronously depletes the primary antioxidant GSH through two distinct mechanisms while simultaneously generating potent cytotoxic •OH. This combined action is designed to disrupt the redox homeostasis of aggressive prostate cancer cells to create an intracellular environment that is both overwhelmed by oxidative damage and highly sensitized to the primary therapeutic mechanism of copper-induced cuproptosis. Fig. 3Nanozyme activity of Cu-EQ NPs in oxidative stress enhancement. (A) Diagram of the mechanism of Ellman’s assay, where DTNB interacts with glutathione (GSH) to yield the yellow TNB2− product that strongly absorbs at 412 nm. UV-Vis spectroscopic changes corresponding to GSH consumption after reaction with increasing concentrations of EGCG-Q (B) and Cu-EQ NPs (C). (D) Quantification of GSH depletion by Cu-EQ NPs at different concentrations. (E) Diagram of POD-like oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) by hydroxyl radicals (•OH), which generates the blue-colored product oxTMB. (F) UV-Vis absorption spectra of TMB oxidation in the presence of hydrogen peroxide (H2O2). (G) Dose-dependent TMB oxidation catalyzed by increasing concentrations of Cu-EQ NPs. (H) Time-dependent change in the UV-Vis absorption spectra of TMB oxidation in the presence of H2O2 and Cu-EQ NPs. (I) Schematic of methylene blue (MB) degradation by hydroxyl radicals (•OH), leading to formation of colorless MB-OH. (J) UV-Vis absorption spectra of MB on reaction with different concentrations of Cu-EQ NPs in the presence of H2O2 (20 mM). (K) UV-Vis absorption spectra of MB on reaction with different concentration of H2O2 (0–80 mM) in the presence of Cu-EQ NPs (5 µg mL− 1). (L) MB degradation by Cu-EQ NPs over time with or without H2O2. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Nanozyme activity of Cu-EQ NPs in oxidative stress enhancement. (A) Diagram of the mechanism of Ellman’s assay, where DTNB interacts with glutathione (GSH) to yield the yellow TNB2− product that strongly absorbs at 412 nm. UV-Vis spectroscopic changes corresponding to GSH consumption after reaction with increasing concentrations of EGCG-Q (B) and Cu-EQ NPs (C). (D) Quantification of GSH depletion by Cu-EQ NPs at different concentrations. (E) Diagram of POD-like oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) by hydroxyl radicals (•OH), which generates the blue-colored product oxTMB. (F) UV-Vis absorption spectra of TMB oxidation in the presence of hydrogen peroxide (H2O2). (G) Dose-dependent TMB oxidation catalyzed by increasing concentrations of Cu-EQ NPs. (H) Time-dependent change in the UV-Vis absorption spectra of TMB oxidation in the presence of H2O2 and Cu-EQ NPs. (I) Schematic of methylene blue (MB) degradation by hydroxyl radicals (•OH), leading to formation of colorless MB-OH. (J) UV-Vis absorption spectra of MB on reaction with different concentrations of Cu-EQ NPs in the presence of H2O2 (20 mM). (K) UV-Vis absorption spectra of MB on reaction with different concentration of H2O2 (0–80 mM) in the presence of Cu-EQ NPs (5 µg mL− 1). (L) MB degradation by Cu-EQ NPs over time with or without H2O2. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Cu-EQ NPs trigger potent anti-cancer activity via cuproptosis-dominant multimodal death pathway Following the confirmation of its catalytic properties, we systematically investigated the therapeutic potential of the Cu-EQ NPs in vitro. A key prerequisite for clinical translation is selective toxicity towards cancer cells. Notably, Cu-EQ NPs exhibited excellent biocompatibility, as evidenced by the maintenance of > 85% viability in the BPH-1 and uroepithelial (SV-HUC-1) cells at therapeutic concentrations (0–40 µg mL− 1) (Fig. 4A, B). We monitored the cellular uptake kinetics in PC3 cells using rhodamine-labeled Cu-EQ NPs and found time-dependent intracellular accumulation (0–7 h), which was quantified based on the progressive increase in red fluorescence intensity (Fig. 4C). A comparative cytotoxicity evaluation of EGCG, EGCG-Q, Cu2+, and Cu-EQ NPs using CCK-8 assay showed that the Cu-EQ NPs exhibited significantly enhanced antitumor efficacy compared with those of its individual components and induced 85.30% PC3 cell death at 40 µg mL− 1 (Fig. 4D). Additionally, this potent lethality was observed in RM-1 cells (Figure S11), which indicates the broad efficacy of the NPs. Furthermore, the distinct superiority of the integrated Cu-EQ NPs compared with those of its individual components is a strong indication of a synergistic therapeutic effect. This long-term efficacy was confirmed using proliferation and clonogenic assays. Cu-EQ NPs elicited the most potent inhibition of PC3 cell proliferation in 120 h (Fig. 4E) and substantially reduced colony formation to 14.7% of that of the control, which highly surpassed the effects of free Cu2+ or EGCG-Q (Fig. 4F, G). This effect likely stems from the prolonged intracellular retention and continuous release of Cu from the NPs, which helped maintain redox disruption and metabolic stress over an extended time duration. Live/dead staining with calcein-AM/PI visually corroborated these findings and showed extensive cell death in the Cu-EQ NP-treated group (Fig. 4H). Finally, we elucidated the mechanisms underlying cell death by using a panel of cell death inhibitors. The copper chelator ammonium tetrathiomolybdate (TTM) significantly rescued PC3 cells from Cu-EQ NP-induced death, which provides direct pharmacological evidence of a copper-dependent death pathway (Fig. 4I). We confirmed the occurrence of cuproptosis at the molecular level by measuring key protein markers. Western blotting analysis showed that Cu-EQ NPs treatment substantially downregulated ferredoxin 1 (FDX1) (86.8% reduction), lipoic acid synthase (LIAS) (81.93% reduction), and lipoylated enzymes (Lip-DLAT and Lip-DLST).(Fig. 4J, K, and S12). Additionally, the expression of ACO2 and NDUFS1 was markedly suppressed, collectively indicating the catastrophic disruption of the TCA cycle and mitochondrial respiratory chain (Fig. 4K, S12). Furthermore, confocal microscopy showed visual cellular DLAT aggregation, which is a definitive hallmark of cuproptosis (Fig. 4L). These enzymatic dysfunctions drive lipoylated protein aggregation and Fe–S cluster destabilization, which induces acute proteotoxic stress that culminates during cuproptosis. Notably, although TTM substantially rescued cell death, the effect was incomplete. In fact, inhibitors of apoptosis (Z-VAD) and ferroptosis (Fer-1) also elicited mild protective effects, which suggests the involvement of other death pathways. This was consistent with the results of Annexin V-FITC/PI staining, which showed a high percentage of positively stained cells (89.3%, Q2 + Q3) after Cu-EQ NP treatment (Fig. 4M). To further validate the robust anti-cancer efficacy across different human prostate cancer models, we performed a comprehensive evaluation using the DU145 cell line. Consistent with the results in PC3 cells, Cu-EQ NPs exhibited efficient cellular uptake, potent inhibition of cell proliferation and colony formation, and induced massive ROS generation and apoptosis in DU145 cells (Figure S13), reinforcing the generalizability of our therapeutic platform. Taken together, these data indicate that Cu-EQ NPs execute a multimodal cytotoxic mechanism. We postulate that the primary driver of cell death is cuproptosis, which is directly triggered by the copper payload from the NPs, as evidenced by the TTM-mediated rescue and downregulation/aggregation of specific molecular markers. This effect is synergistically augmented by apoptosis and ferroptosis, which are likely induced by the potent ROS-generating activity of the nanoreactor, as explained in the previous section This multipronged attack provides a key therapeutic advantage by potentially surmounting the resistance mechanisms that might impede single-pathway agents. Fig. 4Cytotoxicity and cuproptosis mechanisms underlying effect of Cu-EQ NPs on prostate cancer cells. (A, B) Cell viability of normal human prostate epithelial cells (BPH-1) and immortalized ureteral epithelial cells (SV-HUC-1) treated with EGCG, EGCG-Q, Cu2+, and Cu-EQ NPs. (C) Time-dependent uptake of Rhodamine-labeled Cu-EQ NPs in PC3 cells, scale bar = 50 μm. (D) Assessment of PC3 cell viability via CCK-8 assay following exposure to the indicated treatments. (E) Proliferation curve of PC3 cells treated with different compounds over 5 days. (F, G) Clonogenic assay and quantification of colony formation in the different treatment groups. (H) Fluorescence microscopy of PC3 cells under different treatment conditions after co-staining with calcein-AM (live, green) and propidium iodide (PI, dead, red), scale bar = 100 μm. (I) Heatmap of cell viabilities following treatment with Cu-EQ NPs and various cell death inhibitors including ferrostatin-1 (Fer-1), caspase inhibitor Z-VAD-FMK (Z-VAD), belnacasan (VX-765), necrostatin-1 (nec-1), chloroquine (CQ), and tetrathiomolybdate (TTM). (J, K) Immunoblotting analysis assessing core cuproptosis-related proteins (LIAS, FDX1, ACO2, NDUFS1, Lip-DLAT, and Lip-DLST) in PC3 cells after receiving the indicated treatments. (L) Confocal microscopy analysis of DLAT aggregation (via immunofluorescence) within various treatment groups, scale bar = 20 μm. (M) Cell death populations were enumerated using Annexin V-FITC/PI flow cytometry. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Cytotoxicity and cuproptosis mechanisms underlying effect of Cu-EQ NPs on prostate cancer cells. (A, B) Cell viability of normal human prostate epithelial cells (BPH-1) and immortalized ureteral epithelial cells (SV-HUC-1) treated with EGCG, EGCG-Q, Cu2+, and Cu-EQ NPs. (C) Time-dependent uptake of Rhodamine-labeled Cu-EQ NPs in PC3 cells, scale bar = 50 μm. (D) Assessment of PC3 cell viability via CCK-8 assay following exposure to the indicated treatments. (E) Proliferation curve of PC3 cells treated with different compounds over 5 days. (F, G) Clonogenic assay and quantification of colony formation in the different treatment groups. (H) Fluorescence microscopy of PC3 cells under different treatment conditions after co-staining with calcein-AM (live, green) and propidium iodide (PI, dead, red), scale bar = 100 μm. (I) Heatmap of cell viabilities following treatment with Cu-EQ NPs and various cell death inhibitors including ferrostatin-1 (Fer-1), caspase inhibitor Z-VAD-FMK (Z-VAD), belnacasan (VX-765), necrostatin-1 (nec-1), chloroquine (CQ), and tetrathiomolybdate (TTM). (J, K) Immunoblotting analysis assessing core cuproptosis-related proteins (LIAS, FDX1, ACO2, NDUFS1, Lip-DLAT, and Lip-DLST) in PC3 cells after receiving the indicated treatments. (L) Confocal microscopy analysis of DLAT aggregation (via immunofluorescence) within various treatment groups, scale bar = 20 μm. (M) Cell death populations were enumerated using Annexin V-FITC/PI flow cytometry. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Synergistic ROS generation and GSH depletion inflict irreversible organelle and genomic damage After establishing the multimodal cell death pathway, we elucidated the underlying subcellular events that were driven by the catalytic activity of Cu-EQ NPs. We confirmed the induction of severe redox imbalance in PC3 cells using 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA), which is a cell-permeable ROS indicator that undergoes ROS-dependent oxidation to fluorescent DCF. Cu-EQ NP-treated cells exhibited higher DCF fluorescence intensity (Fig. 5A), which confirmed robust ROS generation. Flow cytometric analysis of DCF fluorescence showed that Cu-EQ NPs produced 1.92-fold and 1.57-fold higher median fluorescence intensity (MFI) than those produced by the control and Cu2+ alone, respectively (Fig. 5B). As endogenous GSH plays a cytoprotective role against ROS in cancer cells, we quantified the intracellular GSH levels using a thiol-specific fluorescent probe. EGCG-Q treatment reduced GSH levels by 33.05% via Michael addition adduct formation. Although EGCG alone slightly increased the GSH levels, Cu-EQ NPs triggered a pronounced 87% reduction in intracellular GSH levels (Fig. 5C). The combined effect of massive ROS production with near-total collapse of the GSH antioxidant system creates a highly effective and inescapable state of oxidative stress. This severe redox imbalance initiates a cascade of damage to critical cellular components. Furthermore, we observed extensive lipid peroxidation, which was indicated by the complete fluorescence shift of the BODIPY C11 probe from red to green (Fig. 5D). This signified irreversible damage to the cellular membranes, which aligns with the ferroptosis-like characteristics suggested by the results of our previous inhibitor studies. Quantification using JC-1 potentiometric staining showed pronounced mitochondrial damage induced by elevated ROS levels (Fig. 5E). Control cells maintained high mitochondrial membrane potential (ΔΨm), as evidenced by JC-1 aggregate formation (λem = 590 nm). In contrast, Cu-EQ NPs-treated cells exhibited severe depolarization with predominant JC-1 monomer fluorescence (λem = 530 nm), which indicated complete mitochondrial membrane potential collapse. This functional breakdown was corroborated by TEM analysis, which provided mitochondrial ultrastructural validation. Compared with the typical lamellar cristae organization observed in the control groups, Cu-EQ NP-treated cells exhibited extensive mitochondrial cristae fragmentation with disassembly into vesicular structures accompanied by irregularly shortened and disorganized residual cristae. Additional abnormalities included mitochondrial swelling and blurred inner and outer membranes with focal discontinuities (Fig. 5F). The final consequence of this uncontrolled oxidative assault was extensive DNA damage. Comet assay showed that the control cells exhibited tightly packed round red fluorescence staining, which indicated intact DNA. In contrast, the Cu-EQ NP group showed migration of DNA outside the cell nucleus during electrophoresis with bright tail resembling a comet, which is indicative of severe DNA damage (Fig. 5G). An 8.4-fold increase in Olive tail moment was observed in the Cu-EQ NP-treated group compared with the control group (Fig. 5H). Immunoblotting-based assessment of γ-H2AX expression, which is a direct marker of DNA double-strand breaks, showed a minor 1.24-fold increase in γ-H2AX levels in the Cu2+ group but a 3.12-fold increase in the Cu-EQ NPs group. This indicated a high potential for Cu-EQ NP-induced cellular DNA damage and enhanced ROS-induced cell death (Fig. 5I, J). Based on these findings, we postulate that the Cu-EQ nanoreactor drives an adverse sequence of events via the engineered synergistic effect through the induction of massive ROS with simultaneous depletion of antioxidant defenses to trigger a domino effect that causes progressive and irreparable damage to cellular membranes, mitochondria, and nuclear DNA, leading to inevitable terminal cell death. Fig. 5Cu-EQ NPs disrupt redox homeostasis and induce oxidative stress-mediated cell death. (A) Fluorescence imaging of intracellular ROS generation in cells stained with DCFH-DA after various treatments, scale bar = 100 μm. (B) Flow cytometric quantitation of ROS production in different treatment cohorts. (C) Quantitation of intracellular glutathione (GSH) concentrations after exposure to the indicated treatments. (D) Visualization of lipid peroxidation via fluorescence microscopy using the BODIPY 581/591 C11 probe, scale bar = 100 μm. (E) JC-1 staining to assess mitochondrial membrane potential (ΔΨm). Red fluorescence indicates healthy polarized mitochondria, whereas green suggests mitochondrial damage; scale bar = 100 μm. (F) Ultrastructural analysis of mitochondrial morphology using transmission electron microscopy (TEM) in PC3 cells subjected to different treatments. Representative images at scale bars 5 μm, 2 μm, and 200 nm show hierarchical features from organelle distribution to ultrastructural details. (G) Comet assay (single-cell gel electrophoresis) of PC3 cells subjected to different treatments. Cells with intact DNA appear round, whereas damaged cells exhibit “comet tail” structure. Scale bar, upper: 100 μm, lower: 50 μm. (H) Quantification of Olive tail moment using comet assay to determined extent of DNA damage. (I) Western blotting analysis of γ-H2AX expression. (J) Quantification of γ-H2AX protein abundance from (I). Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Cu-EQ NPs disrupt redox homeostasis and induce oxidative stress-mediated cell death. (A) Fluorescence imaging of intracellular ROS generation in cells stained with DCFH-DA after various treatments, scale bar = 100 μm. (B) Flow cytometric quantitation of ROS production in different treatment cohorts. (C) Quantitation of intracellular glutathione (GSH) concentrations after exposure to the indicated treatments. (D) Visualization of lipid peroxidation via fluorescence microscopy using the BODIPY 581/591 C11 probe, scale bar = 100 μm. (E) JC-1 staining to assess mitochondrial membrane potential (ΔΨm). Red fluorescence indicates healthy polarized mitochondria, whereas green suggests mitochondrial damage; scale bar = 100 μm. (F) Ultrastructural analysis of mitochondrial morphology using transmission electron microscopy (TEM) in PC3 cells subjected to different treatments. Representative images at scale bars 5 μm, 2 μm, and 200 nm show hierarchical features from organelle distribution to ultrastructural details. (G) Comet assay (single-cell gel electrophoresis) of PC3 cells subjected to different treatments. Cells with intact DNA appear round, whereas damaged cells exhibit “comet tail” structure. Scale bar, upper: 100 μm, lower: 50 μm. (H) Quantification of Olive tail moment using comet assay to determined extent of DNA damage. (I) Western blotting analysis of γ-H2AX expression. (J) Quantification of γ-H2AX protein abundance from (I). Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Metabolic disruption amplifies cuproptosis and remodels the immune microenvironment through ICD induction The integrated therapeutic efficacy of Cu-EQ NPs hinges on a synergistic dual assault on tumor metabolism and immunity. To further elucidate the metabolic-immune crosstalk mediated by Cu-EQ NPs, we first characterized the global metabolic landscape. Quantitative analysis of the oxygen consumption rate (OCR) revealed a dramatic reduction in key mitochondrial parameters, including basal respiration, maximal respiration, and spare respiratory capacity (Fig. 6A, Figure S14A). Simultaneously, the extracellular acidification rate (ECAR) profiles and corresponding statistics showed that both glycolysis and glycolytic capacity were significantly suppressed (Fig. 6B, Figure S14B). Consistent with the suppressed glycolytic flux, Cu-EQ NPs treatment led to a significant reduction in glucose uptake, indicating a restriction in the raw material supply for glycolysis (Figure S15A, B, Fig. 6C). Accordingly, the secretion of lactate, the primary byproduct of glycolysis, was markedly decreased in these prostate cancer cell lines (Figure S15C, D, Fig. 6D). At the molecular level, an mRNA expression heatmap showed a coordinated downregulation of key glycolytic enzymes including the rate-limiting enzymes hexokinase 2 (HK2) and phosphofructokinase (PFK) and the terminal enzymes pyruvate kinase M (PKM) and lactate dehydrogenase A (LDHA) (Fig. 6E). Enzyme activity assays confirmed this functional suppression, with the Cu-EQ NPs exhibiting the most potent inhibitory effect across the entire glycolytic cascade (Fig. 6F). This comprehensive inhibition suppresses the primary cellular energy producing pathway, which results in a severe energy crisis, as evidenced by the 56.1% reduction in intracellular ATP levels (Fig. 6G). Notably, Cu-EQ NPs led to a 46.8% downregulation of the ATP-dependent copper efflux pump ATP7B (Fig. 6H, I). This downregulation may be attributed to the conformational instability of ATP7B, a P-type ATPase, under ATP-deficient conditions [35, 36], or its energy-dependent missorting to lysosomal degradation pathways [37]. Furthermore, the EGCG component of our nanoreactor might synergistically suppress ATP7B via the MTF1/ATP7B axis, as evidenced by a recent study [38]. This effect creates a self-amplifying feedback loop of metabolic disruption-induced inhibition of copper export leading to increased intracellular copper accumulation, which potentiates cuproptosis. Lactate plays a major role in fostering immunosuppressive TME. Hence, we investigated Cu-EQ NPs-mediated immunomodulation. Dying cancer cells treated with Cu-EQ NPs released TAAs and DAMPs, which elicited a pro-inflammatory response that was characterized by a 4.01-fold increase in HMGB1 secretion (Figure S16A) and elevated extracellular LDH (1.67-fold), ATP (1.41-fold), and IL-1β (1.39-fold) levels (Figure S16B-D). Immunofluorescence showed nuclear-to-cytoplasmic HMGB1 translocation (25.97% reduction in nuclear retention) (Figs. 6J, S16E) and enhanced calreticulin (CRT) surface exposure (1.39-fold increase), which functions as a potent “eat me” signal to promote the activation of antigen-presenting cells and subsequent phagocytic clearance of dying tumor cells (Figs. 6K, S16F). These DAMPs orchestrate ICD through receptor-mediated interactions. We investigated tumor-associated macrophage (TAM) repolarization by inducing M2 polarization in RAW 264.7 cells using interleukin 4 (IL-4). Conditioned media from Cu-EQ NP-treated cells induced macrophage repolarization from immunosuppressive M2 (CD206high/CD86low) to pro-inflammatory M1 (CD86high/CD206low) phenotypes, which increased the M1 populations from 7.41% to 31.9% and reduced the M2 populations from 39.2% to 9.69% (Fig. 6L). This immunomodulation was validated by cytokine profiling, which showed 1.85-fold elevated IL-12 (M1) and 0.62-fold reduced IL-10 (M2) secretion (Figure S16G, H). Bone marrow-derived dendritic cells (BMDCs) were co-cultured with the treated tumor cells, and their maturation status was assessed using flow cytometry. We found that Cu-EQ NPs significantly enhanced dendritic cell maturation and achieved a 42.1% maturation rate compared with the 27.1%, 22.1%, 28.2%, and 35.2% observed in the control, EGCG, EGCG-Q, and Cu2+ treatment groups, respectively (Fig. 6M). This is consistent with the robust activation mediated by the released TAAs and DAMPs. Additionally, the coordinated DC maturation and TAM repolarization indicated the dual capacity of Cu-EQ NPs to reverse tumor immunosuppression while synergizing with cuproptosis through metabolic-immune crosstalk. In summary, the in vitro data provide compelling evidence for the multifaceted mechanism of Cu-EQ NPs and validate their role as an integrated metabolic–immune nanoreactor. We postulate that the nanoparticles initiate a synergistic attack by crippling glycolysis, which causes an energy crisis and additionally inhibits the ATP7B pump to create a self-amplifying cycle of copper accumulation and cuproptosis. This metabolic assault yields a dual benefit through the reduction of lactate levels, which helps alleviate immunosuppression. The simultaneous occurrence of nanoparticle-induced ICD releases potent danger signals that mature dendritic cells and repolarize tumor-associated macrophages. This creates a virtuous cycle of metabolic collapse that fuels a robust anti-tumor immune response, which effectively dismantles the two primary defense mechanisms of aggressive PCa cells. Fig. 6Cu-EQ NPs induce metabolic and immune reprogramming. (A) Mitochondrial respiration profile of PC3 cells measured by the oxygen consumption rate (OCR) using the Seahorse Cell Mito Stress Test. (B) Glycolytic function profile of PC3 cells measured by the extracellular acidification rate (ECAR). (C) Extracellular glucose consumption of RM-1 cells over 24 h under indicated treatments, normalized to the initial glucose concentration in the medium. (D) Quantification of extracellular lactate levels of RM-1 cells after different treatments. (E) Heatmap of relative mRNA expression in RM-1 cells of key glycolysis-related genes, including those encoding hexokinase 2 (HK2), phosphofructokinase (PFK), pyruvate kinase M2 (PKM), lactate dehydrogenase A (LDHA), glucose-6-phosphate isomerase (GPI), and aldolase A (ALDOA). (F) Heatmap of relative enzymatic activity in RM-1 cells of key glycolytic enzymes (HK, PFK, PK, and LDH) in different treatment groups. (G) Intracellular adenosine triphosphate (ATP) levels of PC3 cells measured after various treatments. (H, I) Western blotting and quantification of ATP7B protein expression levels of PC3 cells using α-Tubulin to confirm equivalent protein loading. (J, K) Confocal microscopy analysis (immunofluorescence) tracking HMGB1 translocation and CRT exposure in RM-1 cells following the indicated treatments, scale bar = 50 μm. (L) Quantitative flow cytometric assessment of DC maturation following their co-culture with the supernatants of pre-treated RM-1 tumor cells. (M) Flow cytometric analysis of macrophage polarization induced by treated RM-1 cell-derived conditioned media. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Cu-EQ NPs induce metabolic and immune reprogramming. (A) Mitochondrial respiration profile of PC3 cells measured by the oxygen consumption rate (OCR) using the Seahorse Cell Mito Stress Test. (B) Glycolytic function profile of PC3 cells measured by the extracellular acidification rate (ECAR). (C) Extracellular glucose consumption of RM-1 cells over 24 h under indicated treatments, normalized to the initial glucose concentration in the medium. (D) Quantification of extracellular lactate levels of RM-1 cells after different treatments. (E) Heatmap of relative mRNA expression in RM-1 cells of key glycolysis-related genes, including those encoding hexokinase 2 (HK2), phosphofructokinase (PFK), pyruvate kinase M2 (PKM), lactate dehydrogenase A (LDHA), glucose-6-phosphate isomerase (GPI), and aldolase A (ALDOA). (F) Heatmap of relative enzymatic activity in RM-1 cells of key glycolytic enzymes (HK, PFK, PK, and LDH) in different treatment groups. (G) Intracellular adenosine triphosphate (ATP) levels of PC3 cells measured after various treatments. (H, I) Western blotting and quantification of ATP7B protein expression levels of PC3 cells using α-Tubulin to confirm equivalent protein loading. (J, K) Confocal microscopy analysis (immunofluorescence) tracking HMGB1 translocation and CRT exposure in RM-1 cells following the indicated treatments, scale bar = 50 μm. (L) Quantitative flow cytometric assessment of DC maturation following their co-culture with the supernatants of pre-treated RM-1 tumor cells. (M) Flow cytometric analysis of macrophage polarization induced by treated RM-1 cell-derived conditioned media. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 In vivo validation of targeted cuproptosis and proliferation inhibition in prostate cancer xenografts In vitro studies confirmed that Cu-EQ NPs induce metabolic reprogramming and redox imbalance by synergistically promoting copper-dependent cell death and immune modulation. We evaluated their therapeutic potential in vivo by assessing the blood compatibility of Cu-EQ NPs. A hemolysis rate of < 5% was observed at 400 µg/mL (Figure S17A), which supports their intravenous safety. Next, we evaluated the in vivo therapeutic effects of Cu-EQ NPs in a xenograft mouse model of PC3 tumors (Fig. 7A). The mice with established tumors were randomized into four treatment groups (n = 5 per group): (1) Control, (2) EGCG-Q, (3) Cu2+, and (4) Cu-EQ NPs. Treatment with Cu-EQ NPs resulted in significant tumor growth suppression compared with that elicited in the control and single-agent (EGCG-Q, Cu2+) arms (Fig. 7B–D) with corresponding reduction in tumor weight and volume (Fig. 7E, F). The superior tumor growth inhibition elicited by Cu-EQ NPs compared with those of its individual components validates the in vivo synergy between their dual mechanisms of metabolic disruption and cuproptosis and is consistent with the in vitro findings. We elucidated the mechanism underlying this potent tumor suppression by performing histological analysis of the excised tumors. Histological examination using H&E staining showed extensive necrotic regions, nuclear shrinkage, and widespread cell death in the Cu-EQ NP-treated tumors (Fig. 7G). TUNEL staining showed extensive apoptosis with quantitative analysis showing 6.77-fold higher apoptotic cells than those in the Cu2+ group (Fig. 7G, S18A). Immunohistochemical (IHC) staining provided direct evidence of the primary mechanism underlying the action of the NPs. We observed a substantial downregulation of FDX1 (73.32% reduction compared with that in the control) and LIAS (81.45% reduction) along with a significant increase in DLAT aggregation in the Cu-EQ NP-treated group (Fig. 7G, S18C-E). These findings validated the in vivo activation of apoptosis. Furthermore, a sharp reduction in the level of the proliferation marker Ki67 (83.38% reduction compared to the control) confirmed that the nanoparticles not only killed existing tumor cells but also potently inhibited their proliferation, which is a critical factor for preventing post-treatment relapse (Fig. 7G, S18B). Notably, biodistribution studies showed the preferential accumulation of copper within the tumor at 12 h post-injection with subsequent systemic clearance from major organs (Fig. 7H), which minimized the potential systemic toxicity. This tumor-targeted accumulation coupled with stable body weights and no observable damage in the H&E-stained major organs throughout the treatment period (Figs. 7I, S17B) confirmed the high biocompatibility and low systemic toxicity of the nanoreactors. Consistent with these robust in vivo results, the Cu-EQ platform’s efficacy stems from its ability to effectively counteract the tumor’s “dual-engine” metabolic plasticity, a capability that single-agent therapies typically lack. The delivered copper ions induce potent TCA cycle-dependent cuproptosis, while the EGCG component simultaneously inhibits the compensatory glycolytic pathway. Mechanistically, this synergistic attack is amplified by built-in chemosensitizing strategies, specifically EGCG-quinone-mediated GSH depletion and the subsequent ATP loss-driven inhibition of the ATP7B efflux pump. This creates a self-reinforcing cycle of intracellular copper accumulation that drives cancer cells into a fatal energy crisis. Beyond its mechanistic efficacy, the structural design of the Cu-EQ nanoreactor offers distinct advantages over existing copper-based nanomedicines. While recent platforms such as copper-organic frameworks or copper-doped mesoporous silica have shown promise, they often face challenges regarding complex synthesis [39, 40], limited drug loading, or the long-term retention of non-biodegradable inorganic matrices. In contrast, our Cu-EQ nanoreactor utilizes a “green” self-assembly strategy based on metal-phenolic networks. This all-organic design is fully biodegradable, thereby minimizing the risk of chronic tissue accumulation while ensuring high loading efficiency of both the metal ion and the chemosensitizing agent. Fig. 7Therapeutic efficacy of Cu-EQ NPs in PC3 xenografts. (A) Schematic diagram outlining the in vivo experimental workflow. (B) Tumor growth in PC3 xenografts in different cohorts. (C) Representative photographs of harvested tumors. (D) Individual trajectories for each mouse within the treatment groups. (E, F) Final tumor weight and volume measurements at the study endpoint. (G) Histological (H&E), TUNEL, and immunohistochemical (Ki67, LIAS, FDX1, DLAT) analysis of tumor sections. scale bar = 50 μm. (H) ICP-MS of Cu content in major organs and tumor after different injection times. (I) Safety evaluation via H&E staining of major organs. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Therapeutic efficacy of Cu-EQ NPs in PC3 xenografts. (A) Schematic diagram outlining the in vivo experimental workflow. (B) Tumor growth in PC3 xenografts in different cohorts. (C) Representative photographs of harvested tumors. (D) Individual trajectories for each mouse within the treatment groups. (E, F) Final tumor weight and volume measurements at the study endpoint. (G) Histological (H&E), TUNEL, and immunohistochemical (Ki67, LIAS, FDX1, DLAT) analysis of tumor sections. scale bar = 50 μm. (H) ICP-MS of Cu content in major organs and tumor after different injection times. (I) Safety evaluation via H&E staining of major organs. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Cuproptosis-triggered immunogenicity transforms “cold” tumors into an immune-permissive landscape Following the observation of the direct tumor-killing effects in the xenograft model, we used an immunocompetent C57BL/6 mouse model bearing syngeneic RM-1 tumors to validate our central hypothesis that Cu-EQ NPs reprogram the TME to achieve superior therapeutic outcomes (Fig. 8A). Initially, the in vivo pharmacokinetic behavior and tumor-targeting efficiency were evaluated using ICG-labeled Cu-EQ NPs. Real-time fluorescence imaging demonstrated that the NPs effectively accumulated at the tumor site, with the signal peaking at 2 h and persisting for up to 48 h (Figure S19A, C). Subsequent ex vivo imaging and semi-quantitative analysis confirmed the systemic distribution and metabolic profile of the NPs. Notably, while the fluorescence signals in major metabolic organs exhibited a progressive decline over time, the reduction rate in tumor tissues was significantly lower, with robust signals persisting for 48 h (Figure S19B, D). This prolonged retention and preferential accumulation strongly validate the EPR-mediated targeting of Cu-EQ NPs, providing a solid foundation for the subsequent systemic therapy. Benefiting from this efficient accumulation, treatment with Cu-EQ NPs resulted in profound tumor regression, as evidenced by a 76.8% reduction in the final tumor volume compared with that observed in the control cohort (Fig. 8B, C, S20). This potent efficacy was mechanistically linked to extensive tumor necrosis (Figure S21A) and robust activation of cuproptosis in the tumor tissue, as evidenced by the downregulation of FDX1/LIAS and increased DLAT aggregation in the tumor tissue (Figure S22A). We confirmed that this cell death was immunogenic. Tumors from the Cu-EQ NP-treated group showed significant ICD hallmarks such as enhanced CRT surface exposure and massive release of nuclear HMGB1 (Fig. 8D, E, S22B–C). This process of immunogenic cell death acts as the crucial trigger for the anti-tumor immune response by effectively turning the tumor itself into an in situ vaccine that broadcasts “danger signals” to mobilize the immune system. Subsequently, these danger signals reshape the innate immune system. Flow cytometric analysis showed a doubling of mature dendritic cells (DCs) (CD80+CD86+) in the tumors of NP-treated mice to 46.1% from 23.8% in the controls (Fig. 8F, S23A). Simultaneously, the NPs reversed the immunosuppressive state of TAMs by significantly increasing the proportion of anti-tumor M1 macrophages (from 7.83% to 14.93%) and decreasing the proportion of pro-tumor M2 macrophages (from 32.13% to 20.43%) (Fig. 8G, S23B, C). This reprogramming of innate immune cells is pivotal because it transforms the TME from an immune-suppressive (“cold”) to an immune-permissive (“hot”) state, which creates a favorable environment for T-cell attack. Moreover, ELISA analysis of the secreted cytokines in the tumor tissues showed that the Cu-EQ NP-treated group showed a 2.08-fold increase in the pro-inflammatory cytokine IL-12 (associated with M1 TAMs) compared with that in the control group, accompanied by a 0.66-fold secretion of the immunosuppressive cytokine IL-10 (linked to M2 TAMs) (Figs. 8H, I). Activation of this innate immune axis effectively primes a powerful adaptive immune response. A pronounced influx of cytotoxic CD8+ T cells was observed in the tumor tissue (Fig. 8J, K), which was corroborated by the significant systemic expansion of the splenic CD8+ T-cell population (28.17% vs. 13.10% in controls) (Fig. 8L, S23D). The functional output of this multifaceted immune activation is a profound shift in the cytokine milieu. Multiplex assays of tumor tissues showed an increase in the key pro-inflammatory and T-cell-activating cytokines such as IFN-γ (2.9-fold), TNF-α (2.0-fold), and IL-6 (3.1-fold) (Fig. 8M–O). Finally, comprehensive safety evaluations including body weight monitoring, organ histology, and serum biochemical and hematological analyses confirmed the excellent in vivo biocompatibility of the Cu-EQ NPs (Figure S21 and S25). In conclusion, our in vivo findings provide a comprehensive validation of the Cu-EQ nanoreactor as a multifaceted therapeutic strategy for advanced PCa. Rather than simple cytotoxicity, Cu-EQ NPs orchestrate a fundamental reprogramming of the tumor microenvironment (TME). By initiating a synergistic “dual-metabolic assault” and self-amplified cuproptosis, this platform ensures that cell death is highly immunogenic. The resulting release of DAMPs successfully converts immunologically “cold” tumors into “hot” environments by promoting dendritic cell maturation and repolarizing tumor-associated macrophages to the anti-tumor M1 phenotype. This orchestrated response culminates in robust CD8 + T cell infiltration, establishing a virtuous cycle where metabolic disruption fuels potent anti-tumor immunity, ultimately leading to profound tumor regression (Fig. 8P). Looking forward, while this study establishes cuproptosis-based nanomedicine as a potent therapeutic strategy, future work should explore optimizing the formulation for active targeting to further enhance specificity in metastatic settings. Additionally, given the robust induction of T-cell infiltration, there is a compelling rationale to investigate the synergistic potential of Cu-EQ with immune checkpoint inhibitors to amplify the therapeutic impact. Collectively, the Cu-EQ nanoreactor represents a comprehensive, rationally designed paradigm that co-opts the metabolic machinery of cancer to drive its own destruction, offering significant potential for clinical application in advanced PCa. Fig. 8Immune response and tumor analysis following Cu-EQ NPs treatment in RM-1 tumor-bearing C57BL/6 mice. (A) Schematic outline of the experimental design. (B) Representative photographs of excised tumors collected from different treatment cohorts. (C) Tumor growth kinetics over the course of the study. Immunofluorescence analysis of CRT exposure (green) (D) and HMGB1 release (red) (E) in tumor tissues from various treatment groups; scale bar = 50 μm. (F) Flow cytometric data quantifying dendritic cell (DC) maturation from tumor tissues. (G) Flow cytometric analysis of macrophage polarization in tumors. Cytokine analysis of tumor supernatants by quantifying IL-12p70 (H) and IL-10 (I) levels. (J, K) Immunofluorescence imaging (J) and quantification (K) of CD8+ T cell infiltration in tumor tissues, scale bar = 50 μm. (L) Flow cytometric analysis of T cells in spleen tissues. (M–O) Measurement of key cytokine levels (IFN-γ, TNF-α, and IL-6) in tumor supernatant from different treatment groups. (P) Diagram of proposed mechanism underlying immune activation via immunogenic cell death (ICD). Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Immune response and tumor analysis following Cu-EQ NPs treatment in RM-1 tumor-bearing C57BL/6 mice. (A) Schematic outline of the experimental design. (B) Representative photographs of excised tumors collected from different treatment cohorts. (C) Tumor growth kinetics over the course of the study. Immunofluorescence analysis of CRT exposure (green) (D) and HMGB1 release (red) (E) in tumor tissues from various treatment groups; scale bar = 50 μm. (F) Flow cytometric data quantifying dendritic cell (DC) maturation from tumor tissues. (G) Flow cytometric analysis of macrophage polarization in tumors. Cytokine analysis of tumor supernatants by quantifying IL-12p70 (H) and IL-10 (I) levels. (J, K) Immunofluorescence imaging (J) and quantification (K) of CD8+ T cell infiltration in tumor tissues, scale bar = 50 μm. (L) Flow cytometric analysis of T cells in spleen tissues. (M–O) Measurement of key cytokine levels (IFN-γ, TNF-α, and IL-6) in tumor supernatant from different treatment groups. (P) Diagram of proposed mechanism underlying immune activation via immunogenic cell death (ICD). Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Conclusion In this study, we have designed and validated an innovative nanoreactor Cu-EQ, which systematically disrupts the defenses of aggressive PCa by effectively integrating a dual-metabolic assault with robust immune activation. The self-assembly of copper ions with the multifunctional agent EGCG enables this nano-platform to counteract the unique “dual-engine” metabolic flexibility of PCa. The delivered copper induces potent TCA cycle-dependent cuproptosis. Simultaneously, the EGCG component cripples the compensatory glycolytic pathway. This synergistic metabolic attack is amplified by the built-in chemosensitizing mechanisms, including EGCG-quinone-mediated GSH depletion and ATP7B copper efflux pump inhibition, which create a self-reinforcing cycle of cell death. Notably, this metabolic collapse is highly immunogenic. The resulting ICD induction converts the “cold” tumor microenvironment into a “hot” inflammatory landscape by promoting dendritic cell maturation and repolarizing macrophages to the anti-tumor M1 phenotype. This orchestrated immune response culminates in the recruitment of potent CD8+ T cells, which establishes a virtuous cycle of metabolically driven cell death that promotes effective anti-tumor immunity. This study provides a new paradigm for treating metabolically complex and immunologically cold tumors by establishing cuproptosis-based nanomedicine as a potent and viable therapeutic strategy. The ability of the Cu-EQ platform to co-opt the metabolic machinery that drives cancer growth and turn it into a fatal vulnerability while simultaneously reversing tumor-induced immunosuppression presents a comprehensive solution to the key challenges in advanced PCa therapy. Future studies should explore the clinical translation of this platform by focusing on optimizing this formulation for targeted delivery. Additionally, its synergistic potential with other immunotherapies such as checkpoint inhibitors must be explored to amplify its therapeutic impact. In summary, this study advances our fundamental understanding of the intricate crosstalk between copper metabolism and anti-tumor immunity and introduces a powerful and rationally designed nanotherapeutic agent with significant potential for clinical application. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1.